Education
About Us
Working with TipRanks
Follow Us
Arcadia Biosciences (RKDA)
NASDAQ:RKDA
Total Valuation
Arcadia Biosciences has a market cap or net worth of $4.81M. The enterprise value is $3.99M.
Market Cap$4.81M
Enterprise Value$3.99M
Share Statistics
Arcadia Biosciences has 1,367,040 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,367,040
Owned by Insiders2.49%
Owned by Institutions0.02%
Financial Efficiency
Arcadia Biosciences’s return on equity (ROE) is -1.13 and return on invested capital (ROIC) is -32.78%.
Return on Equity (ROE)-1.13
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-32.78%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee560.56K
Profits Per Employee-782.00K
Employee Count9
Asset Turnover0.37
Inventory Turnover3.28
Valuation Ratios
The current PE Ratio of Arcadia Biosciences is -1.15. Arcadia Biosciences’s PEG ratio is 0.02.
PE Ratio-1.15
PS Ratio0.00
PB Ratio1.30
Price to Fair Value1.30
Price to FCF-0.84
Price to Operating Cash Flow-0.84
PEG Ratio0.02
Income Statement
In the last 12 months, Arcadia Biosciences had revenue of 5.04M and earned -7.04M in profits. Earnings per share was -5.16.
Revenue5.04M
Gross Profit2.08M
Operating Income-3.65M
Pretax Income-4.31M
Net Income-7.04M
EBITDA-3.65M
Earnings Per Share (EPS)-5.16
Cash Flow
In the last 12 months, operating cash flow was -11.56M and capital expenditures -68.00K, giving a free cash flow of -11.63M billion.
Operating Cash Flow-11.56M
Free Cash Flow-11.63M
Free Cash Flow per Share-8.51
Dividends & Yields
Arcadia Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change92.54%
50-Day Moving Average3.29
200-Day Moving Average3.72
Relative Strength Index (RSI)65.22
Average Volume (3m)11.07K
Important Dates
Arcadia Biosciences upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Arcadia Biosciences as a current ratio of 3.61, with Debt / Equity ratio of 3.36%
Current Ratio3.61
Quick Ratio3.25
Debt to Market Cap0.02
Net Debt to EBITDA1.12
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arcadia Biosciences has paid -8.00K in taxes.
Income Tax-8.00K
Effective Tax Rate<0.01
Enterprise Valuation
Arcadia Biosciences EV to EBITDA ratio is -1.09, with an EV/FCF ratio of -0.41.
EV to Sales0.79
EV to EBITDA-1.09
EV to Free Cash Flow-0.41
EV to Operating Cash Flow-0.41
Balance Sheet
Arcadia Biosciences has $6.58M in cash and marketable securities with ― in debt, giving a net cash position of -$6.23M billion.
Cash & Marketable Securities$6.58M
Total Debt―
Net Cash-$6.23M
Net Cash Per Share-$4.56
Tangible Book Value Per Share$4.54
Margins
Gross margin is 40.11%, with operating margin of -72.31%, and net profit margin of -139.50%.
Gross Margin40.11%
Operating Margin-72.31%
Pretax Margin-85.41%
Net Profit Margin-139.50%
EBITDA Margin-72.31%
EBIT Margin0.00%
Analyst Forecast
The average price target for Arcadia Biosciences is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.00
Price Target Upside210.08% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-6.20%
EPS Growth Forecast64.07%